PT - JOURNAL ARTICLE AU - Pathak, Gita A AU - Wendt, Frank R AU - Goswami, Aranyak AU - De Angelis, Flavio AU - COVID-19 Human Genetics Initiative AU - Polimanti, Renato TI - ACE2 Netlas: In-silico functional characterization and drug-gene interactions of <em>ACE2</em> gene network to understand its potential involvement in COVID-19 susceptibility AID - 10.1101/2020.10.27.20220665 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.27.20220665 4099 - http://medrxiv.org/content/early/2020/10/28/2020.10.27.20220665.short 4100 - http://medrxiv.org/content/early/2020/10/28/2020.10.27.20220665.full AB - Angiotensin-converting enzyme-2 (ACE2) receptor has been identified as the key adhesion molecule for the transmission of the SARS-CoV-2. However, there is no evidence that human genetic variation in ACE2 is singularly responsible for COVID-19 susceptibility. Therefore, we performed a multi-level characterization of genes that interact with ACE2 (ACE2-gene network) for their over-represented biological properties in the context of COVID-19.The phenome-wide association of 51 genes including ACE2 with 4,756 traits categorized into 26 phenotype categories, showed enrichment of immunological, respiratory, environmental, skeletal, dermatological, and metabolic domains (p&lt;4e-4). Transcriptomic regulation of ACE2-gene network was enriched for tissue-specificity in kidney, small intestine, and colon (p&lt;4.7e-4). Leveraging the drug-gene interaction database we identified 47 drugs, including dexamethasone and spironolactone, among others.Considering genetic variants within ± 10 kb of ACE2-network genes we characterized functional consequences (among others) using miRNA binding-site targets. MiRNAs affected by ACE2-network variants revealed statistical over-representation of inflammation, aging, diabetes, and heart conditions. With respect to variants mapped to the ACE2-network, we observed COVID-19 related associations in RORA, SLC12A6 and SLC6A19 genes.Overall, functional characterization of ACE2-gene network highlights several potential mechanisms in COVID-19 susceptibility. The data can also be accessed at https://gpwhiz.github.io/ACE2Netlas/Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe would like to acknowledge support from the National Institutes of Health (R21 DC018098, R21 DA047527, R01 DA12690, F32 MH122058), and thank the COVID-19 Host Genetics Initiative (https://www.covid19hg.org/acknowledgements/) for providing open access to genetic association data.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data used in this study were made publicly available by the cited consortia. This study was exempt from IRB review due to use of deidentified data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data presented is available in above specified link. https://gpwhiz.github.io/ACE2Netlas/